Batavia Biosciences has expertise to generate research viral seed stocks for viral vaccines or vector vaccines that are suitable to be used to generate GMP master virus seed stocks or clinical challenge stocks.
These seed stocks can either be generated from starting virus material or produced synthetically from the virus genome by transfection into a suitable host cell line. We have successfully generated multiple virus seed batches for eg: Influenza, Sabin Polio, Salk Polio, RSV, Rhinovirus and Hepatitis A.
Batavia Biosciences offers a number of cell platforms suitable for generating these viral seed stocks, including HEK293, MDCK and VERO. We also have experience using client specific platforms.